Donepezil

Introduction

Donepezil is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Donepezil (brand name Aricept; also known as E2020) is a piperidine-based, selective, and reversible acetylcholinesterase (AChE) inhibitor used for the symptomatic treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD) across all severity stages. Developed by Eisai Co., Ltd. and co-marketed with Pfizer, donepezil received FDA approval in 1996 for mild-to-moderate AD and remains the most widely prescribed AD medication worldwide. Its long half-life of approximately 70 hours permits convenient once-daily dosing, distinguishing it from other [cholinesterase inhibitors](/entities/cholinesterase-inhibitors) (ChEIs) such as [rivastigmine](/therapeutics/rivastigmine) and [galantamine](/therapeutics/galantamine) ([Sugimoto et al., 2002](https://doi.org/10.2174/1568026023394674)). Donepezil addresses the cholinergic deficit central to the cholinergic hypothesis of AD, which posits that degeneration of cholinergic [neurons](/entities/neurons) in the [nucleus basalis of Meynert](/brain-regions/nucleus-basalis-of-meynert) underlies the cognitive decline observed in AD. [@jann2000]

Mechanism of Action

AChE Inhibition at the Synaptic Cleft

Introduction

Donepezil is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Donepezil (brand name Aricept; also known as E2020) is a piperidine-based, selective, and reversible acetylcholinesterase (AChE) inhibitor used for the symptomatic treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD) across all severity stages. Developed by Eisai Co., Ltd. and co-marketed with Pfizer, donepezil received FDA approval in 1996 for mild-to-moderate AD and remains the most widely prescribed AD medication worldwide. Its long half-life of approximately 70 hours permits convenient once-daily dosing, distinguishing it from other [cholinesterase inhibitors](/entities/cholinesterase-inhibitors) (ChEIs) such as [rivastigmine](/therapeutics/rivastigmine) and [galantamine](/therapeutics/galantamine) ([Sugimoto et al., 2002](https://doi.org/10.2174/1568026023394674)). Donepezil addresses the cholinergic deficit central to the cholinergic hypothesis of AD, which posits that degeneration of cholinergic [neurons](/entities/neurons) in the [nucleus basalis of Meynert](/brain-regions/nucleus-basalis-of-meynert) underlies the cognitive decline observed in AD. [@jann2000]

Mechanism of Action

AChE Inhibition at the Synaptic Cleft

Donepezil exerts its therapeutic effects through selective and reversible inhibition of acetylcholinesterase at the synaptic cleft. By blocking AChE-mediated hydrolysis of [acetylcholine](/entities/acetylcholine), donepezil increases synaptic acetylcholine concentrations in cortical and hippocampal regions, enhancing cholinergic neurotransmission at both muscarinic (M1-M5) and nicotinic (alpha-4-beta-2, alpha-7) receptors. Donepezil binds to both the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE through a mixed competitive and noncompetitive inhibition mechanism, forming multiple hydrogen bonds and hydrophobic interactions with active-site residues ([Sugimoto et al., 2002](https://doi.org/10.2174/1568026023394674)). [@akaike2010]

AChE versus BuChE Selectivity

A defining pharmacological feature of donepezil is its high selectivity for AChE over butyrylcholinesterase (BuChE). In vitro, donepezil inhibits AChE with an IC50 of approximately 6.7 nM while demonstrating 500- to 1,000-fold lower affinity for BuChE, yielding a selectivity ratio exceeding 1,000:1. [This contrasts sharply with [rivastigmine](/entities/rivastigmine) and galantamine, both of which inhibit BuChE to a clinically meaningful degree. The high AChE selectivity of donepezil may contribute to its favorable gastrointestinal tolerability profile, as BuChE is abundant in peripheral tissues including the gut ([Jann, 2000](https://doi.org/10.2165/00003088-200039020-00005)). [@rogers]

| Property | Donepezil | [Rivastigmine](/therapeutics/rivastigmine) | Galantamine | [@rogersa]
|----------|-----------|--------------|-------------| [@winblad2006]
| AChE IC50 | 6.7 nM | 4.4 nM | 0.35 microM | [@birks2006]
| BuChE inhibition | Minimal (ratio >1,000:1) | Substantial (ratio ~1:1) | Moderate (ratio ~50:1) | [@howard2012]
| Inhibition type | Reversible, mixed | Pseudo-irreversible, carbamate | Reversible, competitive | [@farlow2010]
| Nicotinic modulation | None | None | Allosteric potentiating ligand | [@nakamura2023]

Additional Mechanisms

Beyond cholinesterase inhibition, donepezil has been reported to exert neuroprotective effects including reduction of glutamate-induced excitotoxicity, attenuation of [amyloid-beta](/proteins/amyloid-beta)-mediated neurotoxicity, and upregulation of nicotinic alpha-7 receptor expression. These pleiotropic effects remain secondary to its primary cholinergic mechanism ([Akaike et al., 2010](https://doi.org/10.1111/j.1471-4159.2010.06993.x)). [@hansen2008]

Pharmacokinetics

| Parameter | Value | [@courtney2004]
|-----------|-------| [@tariot2004]
| Oral bioavailability | ~100% | [@whitehead2004]
| Time to peak (Tmax) | 3-4 hours | [@galantamine]
| Protein binding | 96% (primarily albumin) | [@memantine]
| Volume of distribution | 12-16 L/kg | [@acetylcholine]
| [BBB](/entities/blood-brain-barrier) penetration | CSF concentrations ~50% of plasma | [@cholinergic]
| Primary metabolism | Hepatic: CYP2D6 (major), CYP3A4 (minor) | [@alzheimers]
| Elimination half-life | ~70 hours | [@rivastigmine]
| Steady-state attainment | ~21 days (3 half-lives) | [@memantinea]
| Excretion | 57% renal (as metabolites), 15% fecal, 28% unrecovered | [@drugbank]

Donepezil is nearly completely absorbed orally regardless of food intake. Metabolism occurs through CYP2D6-mediated O-demethylation and CYP3A4-mediated N-dealkylation. Caution is warranted with concurrent CYP2D6 inhibitors (paroxetine, fluoxetine) or CYP3A4 inducers (carbamazepine, phenytoin) ([Jann, 2000](https://doi.org/10.2165/00003088-200039020-00005)). [@pubchem]

Clinical Efficacy

Pivotal Trials in Mild-to-Moderate AD

Donepezil's approval was based on two pivotal phase III trials conducted by Rogers and colleagues. The first, a 15-week double-blind, placebo-controlled study at 23 U.S. centers, randomized patients with mild-to-moderate AD (MMSE 10-26) to placebo, donepezil 5 mg/day, or donepezil 10 mg/day. At endpoint, the drug-placebo differences for the 5 mg and 10 mg groups were, respectively, 2.5 and 3.1 points on the ADAS-Cog (P < 0.001), 0.3 and 0.4 points on the CIBIC-Plus (P <= 0.008), and 1.0 and 1.3 points on the MMSE ([Rogers et al., 1998a](https://doi.org/10.1001/archinte.158.9.1021)). [@fda2012]

The second pivotal trial was a 24-week study randomizing 473 patients to placebo, donepezil 5 mg/day, or donepezil 10 mg/day. Both donepezil groups showed significant improvement on the ADAS-Cog (mean improvement of 2.5-3.0 points vs. placebo; P < 0.001) and the CDR-SB. Benefits were observed across cognitive domains including memory, attention, language, and praxis ([Rogers et al., 1998b](https://doi.org/10.1212/WNL.50.1.136)). [@pubmed]

Severe AD Trials

The landmark Winblad et al. (2006) trial demonstrated donepezil's efficacy in severe AD (MMSE 1-10). In this double-blind, placebo-controlled, 6-month study of 248 nursing home residents, donepezil-treated patients showed significant improvement on the Severe Impairment Battery (SIB) (treatment difference: 5.7 points; P = 0.008) and less decline on the ADCS-ADL-severe scale compared to placebo ([Winblad et al., 2006](https://doi.org/10.1016/S0140-6736(06)68350-5)).

Efficacy Summary Across Outcome Measures

| Outcome Measure | Domain | Donepezil Effect vs. Placebo |
|-----------------|--------|------------------------------|
| ADAS-Cog (70-point) | Cognition | 2.5-3.5 point improvement |
| MMSE (30-point) | Cognition | 1.0-1.8 point improvement |
| SIB (severe AD) | Cognition | 5.7 point improvement |
| CDR-SB | Global function | 0.5-1.0 point less decline |
| CIBIC-Plus | Clinician global | Significant improvement (P < 0.01) |
| ADCS-ADL | Daily function | Slower decline (P < 0.05) |

The number needed to treat (NNT) for a clinically meaningful response ranges from 8 to 12 patients across trials ([Birks, 2006](https://doi.org/10.1002/14651858.CD005593)).

Donepezil + Memantine Combination Therapy: The DOMINO Trial

The DOMINO-AD (Donepezil and Memantine in Moderate to Severe [Alzheimer's](/diseases/alzheimers-disease) Disease) trial, published in the New England Journal of Medicine, was a landmark factorial-design study of 295 patients with moderate-to-severe AD (MMSE 5-13) already receiving donepezil. Patients were randomized to: continue donepezil, discontinue donepezil and switch to placebo, discontinue donepezil and start [memantine](/therapeutics/memantine), or continue donepezil and add memantine. Over 52 weeks, continued donepezil was associated with a mean MMSE benefit of 1.9 points (95% CI: 1.3-2.5; P < 0.001) and BADLS (Bristol Activities of Daily Living Scale) benefit of 3.0 points (95% CI: 1.8-4.3; P < 0.001) compared with donepezil discontinuation. [Memantine](/therapeutics/memantine) monotherapy also showed cognitive benefits versus placebo but was not significantly superior to donepezil. Notably, the combination of donepezil plus memantine did not demonstrate significant additional benefit over donepezil alone on either primary endpoint, though post-hoc analyses using different statistical approaches suggested modest additive effects on some measures ([Howard et al., 2012](https://doi.org/10.1056/NEJMoa1106668)).

Dosing and Formulations

Standard Oral Dosing

| Phase | Dose | Duration |
|-------|------|----------|
| Initiation | 5 mg once daily | 4-6 weeks minimum |
| Maintenance (mild-moderate) | 10 mg once daily | Ongoing |
| Severe AD | 23 mg once daily | After >= 3 months stable on 10 mg |

23 mg Extended-Release Formulation

Approved by the FDA in July 2010, the 23 mg sustained-release tablet was developed for patients with moderate-to-severe AD already stable on donepezil 10 mg. The matrix-type formulation uses a sustained-release technology that avoids sharp peak concentrations despite delivering a higher daily dose. In the pivotal study of over 1,400 patients (Farlow et al., 2010), donepezil 23 mg showed significantly greater cognitive benefits on the SIB compared to 10 mg (treatment difference: 2.2 points; P < 0.001), though the co-primary global function endpoint (CIBIC-Plus) did not reach significance. Gastrointestinal side effects were more common during the dose-escalation period ([Farlow et al., 2010](https://doi.org/10.1007/s40263-013-0051-2)).

Transdermal Patch (ADLARITY)

ADLARITY (Corium, Inc.) is the first once-weekly donepezil transdermal delivery system, approved by the FDA in 2022 for all stages of AD dementia. The patch uses a reservoir technology converting donepezil hydrochloride to the more skin-permeable freebase form, delivering steady-state plasma concentrations bioequivalent to oral donepezil 5 or 10 mg/day. A phase III study in Japan demonstrated non-inferiority of the 27.5 mg patch to oral donepezil 5 mg tablets over 24 weeks on cognitive measures. The transdermal route reduces GI exposure and first-pass metabolism, potentially improving tolerability in patients with swallowing difficulties or GI sensitivity ([Nakamura et al., 2023](https://doi.org/10.1111/ggi.14566)).

Adverse Effects

Common Side Effects

Donepezil's adverse effect profile reflects cholinergic excess, predominantly affecting the gastrointestinal and nervous systems:

• Gastrointestinal: Nausea (11%), diarrhea (8-10%), vomiting (5-8%), anorexia (4%), weight loss
• Neurological: Insomnia (9%), vivid dreams (7%), headache (7%), dizziness (5%)
• Musculoskeletal: Muscle cramps (6%), fatigue (4%)
• Cardiac: Bradycardia (1-3%), syncope (<2%), QT prolongation (rare)

Comparison of Cholinesterase Inhibitors

| Feature | Donepezil | [Rivastigmine](/therapeutics/rivastigmine) | Galantamine |
|---------|-----------|--------------|-------------|
| Chemical class | Piperidine | Carbamate | Phenanthrene alkaloid |
| AChE inhibition | Selective, reversible | Dual (AChE + BuChE), pseudo-irreversible | Selective, reversible |
| BuChE inhibition | Minimal | Yes (equipotent) | Mild |
| Nicotinic receptor | No direct effect | No direct effect | Allosteric potentiating ligand |
| Half-life | ~70 hours | ~1.5 hours (oral) | ~7 hours |
| Dosing frequency | Once daily | Twice daily (oral); once daily (patch) | Twice daily (IR); once daily (ER) |
| CYP metabolism | CYP2D6, CYP3A4 | Minimal hepatic | CYP2D6, CYP3A4 |
| Transdermal patch | Yes (ADLARITY, weekly) | Yes (Exelon Patch, daily) | No |
| FDA-approved for severe AD | Yes (23 mg) | Yes (patch) | No |
| FDA-approved for PD dementia | No | Yes | No |
| ADAS-Cog benefit vs. placebo | 2.5-3.5 points | 2.0-3.0 points | 2.5-3.5 points |
| GI tolerability | Best | Worst (oral); better (patch) | Intermediate |

Meta-analyses indicate no statistically significant differences in overall cognitive efficacy among the three ChEIs, though indirect comparisons suggest slightly higher global response rates with donepezil and rivastigmine compared with galantamine. Tolerability is generally best with donepezil, owing to its high AChE selectivity and once-daily dosing ([Hansen et al., 2008](https://doi.org/10.2147/CIA.S12159936); [Birks, 2006](https://doi.org/10.1002/14651858.CD005593)).

Limitations as Symptomatic Therapy

Donepezil provides symptomatic relief without altering the underlying neurodegenerative process. Benefits are modest (stabilization of 6-12 months of decline on average), and individual response is variable. The AD2000 trial, a 3-year pragmatic study, found statistically significant but clinically marginal MMSE benefits (0.8 points; P = 0.004) with no delay in institutionalization or disability progression ([Courtney et al., 2004](https://doi.org/10.1016/S0140-6736(04)16681-4)). Discontinuation often results in rapid cognitive decline to the level expected without treatment, underscoring the purely symptomatic nature of the effect. Unlike disease-modifying therapies targeting [amyloid-beta](/proteins/amyloid-beta) (e.g., [lecanemab](/entities/lecanemab), aducanumab) or tau] protein], donepezil does not reduce pathological protein burden or slow neuronal loss. Nevertheless, it remains a guideline-recommended first-line treatment given its established safety profile, ease of use, and low cost as a generic medication.

Brain Atlas Resources

• Allen Human Brain Atlas: [Donepezil expression search](https://human.brain-map.org/microarray/search/show?search_term=Donepezil)
• Allen Mouse Brain Atlas: [Donepezil search](https://mouse.brain-map.org/search/index.html?query=Donepezil)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Donepezil developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Donepezil)

See Also

• [Index](/index)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Background

The study of Donepezil has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Donepezil discovered through SciDEX knowledge graph analysis: